#Simnotrelvir
Schnelle Senkung der Viruslast.
Etwas stärker wirksam sein als die beiden Konkurrenten.
„eindeutig wirksames Medikament“
Nicht bekannt, ob Zulassung in den USA und Europa angestrebt wird. 🤔

www.aerzteblatt.de/nachrichten/...
COVID-19: Simnotrelvir beschleunigt Erholung bei milden Erkrankungen
Peking – Das Virustatikum Simnotrelvir, das wie der Paxlovid-Wirkstoff Nirmatrelvir und das in Japan zugelassene Ensitrelvir die 3CL-Protease von SARS-CoV-2... #NEJM #COVID19 #Simnotrelvir
www.aerzteblatt.de
January 18, 2024 at 5:54 PM
Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19
www.nejm.org/doi/full/10.....
January 19, 2024 at 2:41 PM
However, comprehensive data are required to confirm the efficacy and safety of simnotrelvir/ritonavir and leritrelvir.
www.sciencedirect.com/science/arti...
Recap
www.mdpi.com/2076-2607/12...
Small-molecule antiviral treatments for COVID-19: A systematic review and network meta-analysis
This study aimed to explore the efficacy and safety of small-molecule antivirals for treating coronavirus disease 2019 (COVID-19).Seven databases were…
www.sciencedirect.com
June 19, 2024 at 11:56 AM
MedSky🧪#IDSky #Drugsdevelopment #Clinicaltrial Evaluate the Efficacy and Safety of SIM0417 /Oral #Simnotrelvir Orally Co-Administered With #Ritonavir in Symptomatic Adult Participants With Mild to Moderate #COVID19

www.nejm.org/doi/10.1056/...
Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19 | NEJM
Original Article from The New England Journal of Medicine — Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19
www.nejm.org
January 23, 2024 at 7:24 AM
the simnotrelvir trial was conducted on mostly healthy young adults, none of whom had severe symptoms. The study included 1,208 patients enrolled at 35 sites in China; 603 were assigned to receive simnotrelvir, and 605 to receive placebo .
www.cidrap.umn.edu/covid-19/ora...
Oral antiviral simnotrelvir shows promise for treating mild COVID-19
The length of COVID-19 symptoms was on average 36 hours shorter in the simnotrelvir group.
www.cidrap.umn.edu
January 18, 2024 at 6:53 PM
MedSky🧪 #IDSky +ve trial results of #simnotrelvir, an oral antiviral that can shorten the duration of mild to moderate #COVID19 symptoms. Unlike with Paxlovid or other antivirals tested against the virus,
www.nejm.org/doi/full/10....
January 18, 2024 at 6:50 PM
NEJM: Oral Simnotrelvir for Mild-to-Moderate Covid, RCT from China buff.ly/3S3bVx1

750 mg simnotrelvir +100 mg ritonavir twice daily for 5 days, start by day 3 of illness

Faster resolution of symptoms and especially respiratory symptoms and decreased viral load. Cheaper too.

🩺😷🛟💊
January 18, 2024 at 5:15 AM
Potent new pill provides COVID relief for the masses: The drug simnotrelvir shortens symptoms for those with mild infections and is sold at a lower price in China than its main rival. www.nature.com/articles/d41...
Potent new pill provides COVID relief for the masses
The drug simnotrelvir shortens symptoms for those with mild infections and is sold at a lower price in China than its main rival. The drug simnotrelvir shortens symptoms for those with mild infections...
www.nature.com
January 18, 2024 at 4:42 PM
"SARS-COV-2: Neues Medikament verkürzt milde Corona-Verläufe.
Das antivirale Mittel Simnotrelvir lindert Fieber, Husten und Schnupfen bei Patienten, die kein hohes Risiko für schwere Verläufe haben. Bislang ist es nur in China zugelassen."

#CovidIsNotOver #MaskUp #TeamVorsicht #LongCovid
January 18, 2024 at 6:12 PM
There are several promising oral antivirals in the pipeline with completed Ph3 studies
Ensitrelvir - jamanetwork.com/journals/jam...
Simnotrelvir www.nejm.org/doi/full/10....
Olgotrelvir (Ovydso): evidence.nejm.org/doi/full/10....
Rendesivir which is IV can be used in kids >28 days who weigh >3kg
New Antiviral on the Horizon for Mild to Moderate COVID-19
COVID-19 symptoms improved 24 hours sooner among patients with mild to moderate infection who received ensitrelvir, an investigational antiviral drug, than those who received a placebo, according to r...
jamanetwork.com
February 14, 2025 at 7:01 PM
Columbia University scientists found SARS-CoV-2 can quickly evolve resistance to several leading COVID antivirals.

Some mutations made the virus resistant to multiple drugs at once, raising concerns about future treatment options.

www.nature.com/articles/s41...
Cross-resistance patterns in SARS-CoV-2 against 3CL protease inhibitors - Nature Communications
SARS-CoV-2 can develop resistance to antivirals. Here, the authors identify the pathways utilized by the virus to attain resistance to atilotrelvir, ibuzatrelvir, and simnotrelvir, revealing extensive...
www.nature.com
May 19, 2026 at 10:26 AM
Researchers found SARS-CoV-2 evolved T21I and E166A mutations that make key antivirals like simnotrelvir and nirmatrelvir less effective, yet bofutrelvir still binds well, suggesting some drugs can overcome resistance.

journals.asm.org/doi/10.1128/...
SARS-CoV-2 3CLpro mutations T21I and E166A confer differential resistance to simnotrelvir, bofutrelvir, and ensitrelvir | Journal of Virology
Considering that the nirmatrelvir-resistant SARS-CoV-2 has emerged in immunocompromised patients who received long-term Paxlovid therapy, it is essential to investigate the response of resistance 3CLp...
journals.asm.org
April 27, 2026 at 11:40 AM
Simnotrelvir shows strong antiviral activity against major Omicron variants, including XBB.1.5 and JN.1.

It also works against drug-resistant strains, suggesting it could be a powerful tool against evolving SARS-CoV-2.

journals.asm.org/doi/10.1128/...
Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrier | Antimicrobial Agents and Chemotherapy
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged at the end of 2019, causing severe acute respiratory coronavirus disease 2019 (COVID-19) and triggering a global pandemic (1, 2...
journals.asm.org
March 10, 2025 at 9:40 PM
標準的リスクの人にも使えてパキロビッドの約1/4の価格の新型コロナ用抗ウイルス薬「シムノトレルビル」に期待が集まっている。

日本は4月からパキロビッドなどが3万円程度になるし、シムノトレルビルが新たな選択肢となって欲しい🥺(本当に有効ならば)

「中国産だから使いたくない」と言う人も出そうだけど。。。

www.nature.com/articles/d41...
Potent new pill provides COVID relief for the masses
The drug simnotrelvir shortens symptoms for those with mild infections and is sold at a lower price in China than its main rival. The drug simnotrelvir shortens symptoms for those with mild infections...
www.nature.com
February 2, 2024 at 11:07 PM
A new drug called simnotrelvir has been shown to speed recovery from mild to moderate disease by about 1.5 days1.
Potent new pill provides COVID relief for the masses
The drug simnotrelvir shortens symptoms for those with mild infections and is sold at a lower price in China than its main rival. The drug simnotrelvir shortens symptoms for those with mild infections...
www.nature.com
January 18, 2024 at 8:45 PM
Simnotrelvir: Another antiviral option to treat Covid? www.nature.com/articles/d41...
January 18, 2024 at 7:34 PM
Simnotrelvir shortens symptoms for those with mild #Covid infections https://www.nature.com/articles/d41586-024-00117-5
#Antivirals #ClinicalTrial
January 20, 2024 at 12:13 PM
MIDD sped up simnotrelvir COVID-19 drug approval🇨🇳: 90.6% hit EC90 dose, 750mg cut viral load by −4.995 vs −4.236 (P=0.0367), 1.5-day symptom relief, no serious AEs.🚀##idsky
Model-informed drug development in public health emergency of international concern: accelerating marketing authorization of simnotrelvir
ABSTRACTDuring a Public Health Emergency of International Concern (PHEIC), rapid drug development is critical, but traditional clinical trials are time-consuming and high-risk. This study used coronavirus disease 2019 (COVID-19) as an example to highlight the pivotal role of model-informed drug development (MIDD) in expediting the marketing authorization of simnotrelvir in China, a 3CLpro inhibitor for COVID-19 treatment. Three simnotrelvir clinical trials (Phase Ia, Ib, II/III) were optimized using the MIDD approach. Pharmacokinetics was investigated using nonlinear mixed-effects models, exposure was calculated through Monte Carlo simulation and Bayes estimation, and exposure-efficacy/safety relationships were analyzed using linear/logistic regression models. The MIDD approach began with a translational study to predict patients’ starting doses using first-in-human data, preclinical data, and pharmacodynamic surrogate marker. A dose level of 750 mg/100 mg simnotrelvir/ritonavir was recommended, using simulation results with 90.6% of participants’ trough concentration exceeding EC90 for anti-Omicron variant. Then, a biomarker confirmation study to investigate dose-exposure-response relationship found that 750 mg suppressed viral load more than 300 mg (−4.995 vs. −4.236 log10 copies/mL, P = 0.0367) in Phase Ib. Finally, a randomized controlled trial to confirm benefit-risk ratio found that simnotrelvir/ritonavir reduced time to sustained resolution of 11 clinical syndromes by 1.5 days compared with placebo, had no serious adverse events, and had a flat exposure-response relationship with viral load reduction, time to sustained resolution, and ≥2 grade treatment-emergent adverse event rate with approved dosage. MIDD enhanced clinical trial success, optimized the benefit-risk profile, and expedited marketing authorization for new drug development in response to PHEIC.CLINICAL TRIALSThis study is registered with ClinicalTrials.gov as NCT05339646, NCT05369676, and NCT05506176.
journals.asm.org
December 2, 2025 at 6:30 PM
Simnotrelvir, an antiviral for SARS-CoV-2, showed strong efficacy against Omicron variants. It inhibited nirmatrelvir-resistant mutants and maintained efficacy despite resistance. 💊📉##idsky
Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrier
ABSTRACTSimnotrelvir is an oral small-molecule antiviral agent targeting the 3C-like protease (3CLpro) of SARS-CoV-2, proven effective against the Delta variant with favorable pharmacokinetics and safety in preclinical study. In this study, we further evaluated the antiviral efficacy of simnotrelvir against a range of emerging Omicron variants, including BA.1, BA.4, BA.5, CH.1.1, XBB.1.5, XBB.1.16, EG.5, and JN.1. In vitro assays with Vero E6 cells confirmed that simnotrelvir exhibited robust antiviral activity across these variants, comparable to the Food and Drug Administration (FDA)-approved drug nirmatrelvir. Additionally, simnotrelvir demonstrated effective inhibition against several nirmatrelvir-resistant SARS-CoV-2 3CLpro mutants, including A260V, Y54A, (T21I + S144A), F140A, H172Y, and E166V. Importantly, simnotrelvir showed better potency against the E166V mutation compared to nirmatrelvir. Resistance selection studies revealed that BA.5 developed reduced sensitivity after 5 and 10 passages, increasing the IC50 values by 3.2 and 4.5-fold, respectively, while HCoV-OC43 showed an 8.3-fold increase after 12 passages. Despite this, simnotrelvir’s overall efficacy remains strong. Furthermore, clinical trials demonstrated that combining simnotrelvir with ritonavir significantly shortened symptom resolution in COVID-19 patients. Genomic analysis of treated patients found random nucleotide substitutions but no significant mutations linked to 3CLpro resistance. In conclusion, simnotrelvir shows strong antiviral activity against SARS-CoV-2 variants and maintains a high barrier to resistance, reinforcing its potential as an effective therapeutic option for current and future SARS-CoV-2 variants.
journals.asm.org
March 22, 2025 at 8:00 AM